University of Groningen

Imaging and biomarkers to aid in treatment decisions in melanoma and rectal cancer

Bisschop, Kees

DOI:
[10.33612/diss.157532721](https://doi.org/10.33612/diss.157532721)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Bisschop, K. (2021). *Imaging and biomarkers to aid in treatment decisions in melanoma and rectal cancer*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.
<https://doi.org/10.33612/diss.157532721>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Imaging and biomarkers to aid in treatment decisions in melanoma and rectal cancer

Cornelis Bisschop

The printing of this thesis was financially supported by the Stichting Beroepsopleiding Huisartsen (SBOH), Stichting Werkgroep Interne Oncologie, Rijksuniversiteit Groningen, Universitair Medisch Centrum Groningen, Uitgeverij Jaap, Noord Negentig, and are gratefully acknowledged.

Layout: Douwe Oppewal, www.oppewal.nl

Printing: Ipskamp Printing, Enschede

© Copyright 2020, C. Bisschop. All rights reserved. No part of this thesis may be reproduced in any form or by any means without prior permission of the author.

rijksuniversiteit
 groningen

Imaging and biomarkers to aid in treatment decisions in melanoma and rectal cancer

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
woensdag 31 maart 2021 om 16:15 uur

door

Cornelis Bisschop

geboren op 23 mei 1989
te Elburg

Promotor

Prof. dr. G.A.P. Hospers

Copromotor

Dr. M. Jalving

Beoordelingscommissie

Prof. dr. J.T.M. Plukker

Prof. dr. J.B.A.G. Haanen

Prof. dr. A.W.J.M. Glaudemans

Paranimfen

Niek Casteleijn

Gerwin van Wijhe

Contents

Chapter 1	General introduction and outline of the thesis	9
Chapter 2	Rational use of FDG PET/CT in patients with advanced cutaneous melanoma: a critical review. <i>Crit Rev Oncol Hematol.</i> 2020 Jul; epub	19
Chapter 3	Rapid BRAF Mutation Tests in Patients with Advanced Melanoma: Comparison of Immunohistochemistry, Droplet Digital Polymerase Chain Reaction and the Idylla Mutation Platform. <i>Melanoma Res.</i> 2018 Apr;28(2):96-104..	51
Chapter 4	Serum S100B as a tumor marker of response during treatment with ipilimumab or PD-1 inhibitor.	71
Chapter 5	Association between pembrolizumab related adverse events and treatment outcome in advanced melanoma: Results from the Dutch expanded access program. <i>J Immunother.</i> 2019 Jul/Aug;42(6):208-214	91
Chapter 6	Diagnosis and treatment of intestinal melanoma metastases in the era of effective systemic treatment.	113
Chapter 7	Consequence of restaging after neoadjuvant treatment for locally advanced rectal cancer. <i>Ann Surg Oncol.</i> 2015 Feb;22(2):552-6.	133
Chapter 8	Short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical treatment in primary stage IV rectal cancer. Long-term results of a phase II study. <i>Ann Surg Oncol.</i> 2017 Sep;24(9):2632-2638.	147
Chapter 9	Summary	163
Chapter 10	Nederlandse samenvatting (Dutch summary)	171
	Dankwoord (Acknowledgments)	179